Effects of vasopressin on portal-systemic collaterals of cirrhotic rats

References

• Conn HO. Vasopressin and nitroglycerin in the treatment of bleeding varices: thebottom line. Hepatology 1986;6:523–5.
   PubMed Web of Science ®Google Scholar
• Iwao T, Toyonaga A, Oho K, Shigemori H, Sakai T, Tayama C, et al. Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. J Hepatol 1996;25:491–7.
   PubMedGoogle Scholar
• Lee FY, Tsai YT, Lin HC, Lee SD, Hsia HC, Lin WJ, et al. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J Hepatol 1992;15:54–8.
   PubMedGoogle Scholar
• Iwao T, Toyonaga A, Ikegami M, Sumino M, Oho K, Sakaki M, et al. Portohepatic pressures, hepatic function, and blood gases in the combination of nitroglycerin and vasopressin: search for additive effects in cirrhotic portal hypertension. Am J Gastroenterol 1992;87:719–24.
   PubMedGoogle Scholar
• Ohnishi K, Saito M, Nakayama T, Hatano H, Okuda K. Effects of vasopressin on portal hemodynamics in patients with portal hypertension. Am J Gastroenterol 1987;82:135–8.
   Google Scholar
• Bosch J, Mastai R, Kravetz D, Bruix J, Rigau J, Rodes J. Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. J Hepatol 1985;1:125–39.
   Google Scholar
• Bosch J, Bordas JM, Mastai R, Kravetz D, Navasa M, Chesta J, et al. Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure. Hepatology 1988;8:861–5.
   PubMed Web of Science ®Google Scholar
• Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630–5.
   PubMed Web of Science ®Google Scholar
• Pizcueta MP, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJ, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992;103:1909–15.
   PubMed Web of Science ®Google Scholar
• Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20–7.
   PubMedGoogle Scholar
• Kimpel M, Folz IC, Hanisch E. Time course-dependent evolution of nitric oxide-mediated arterial hyporeactivity to phenylephrine in rats with ligated bile duct. Scand J Gastroenterol 1998;33:314–8.
   Google Scholar
• Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979;48:895–900.
   Google Scholar
• Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Chu CJ, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001;3:816–20.
   Google Scholar
• Franco F, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction: effect of bile diversion on portal pressure in the rat. Arch Surg 1979;114:1064–7.
   PubMedGoogle Scholar
• Cameron GR, Muzaffar Hasan S. Disturbances of structure and function in the liver as the result of biliary obstruction. J Pathol Bacteriol 1958;75:333–49.
   PubMedGoogle Scholar
• Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct ligation obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305–11.
   Google Scholar
• Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992;263:G544–50.
   PubMedGoogle Scholar
• Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane “lung” for small organ perfusions. J Lipid Res 1974;15:182–6.
   PubMed Web of Science ®Google Scholar
• Fernandéz M, Pizcueta P, García-Pagán JC, Feu F, Cirera I, Bosch J, et al. Effects of ritanserin, a selective and specific S2-serotoninergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993;18: 389–93.
   Google Scholar
• Castaneda B, Debernardi-Venon W, Bandi JC, Andreu V, Perez del Pulgar S, Moitinho E, et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000;31:581–6.
   Google Scholar
• Pang CC, Tabrizchi R. The effects of noradrenaline, B-HT 920, methoxamine, angiotensin II and vasopressin on mean circulatory filling pressure in conscious rats. Br J Pharmacol 1986;89:389–94.
   PubMed Web of Science ®Google Scholar
• Ranek L, Vilstrup H, Iversen J, Petersen P, Milandri M. The effect of continuous vasopressin infusion on splanchnic blood flow, liver function, and portal and central venous pressures in patients with cirrhosis. Scand J Clin Lab Invest 1984;44:251–6.
   Google Scholar
• Rothe CF, Maass-Moreno R. Active and passive liver microvascular responses from angiotensin, endothelin, norepinephrine, and vasopressin. Am J Physiol 2000;279: H1147–56.
   Google Scholar
• Yang MC, Yu PC, Tu MS, Lay CS, Hong CY, Chou CK, et al. Effects of endothelin and vasopressin on portal pressure of rats. Life Sci 1990;46:1929–36.
   PubMed Web of Science ®Google Scholar
• Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235–9.
   PubMed Web of Science ®Google Scholar
• Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of NG-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464–70.
   PubMed Web of Science ®Google Scholar
• Casadevall M, Panés J, Piqué JM, Marroni N, Bosch J, Whittle BJ. Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. Hepatology 1993;18:628–34.
   PubMed Web of Science ®Google Scholar
• Pizcueta MP, Pique JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105:184–90.
   Google Scholar
• Guarner F, Guarner C, Prieto J, Colina I, Quiroga J, Casas J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986;90:687–94.
   PubMed Web of Science ®Google Scholar
• Hsia HC, Lin HC, Tsai YT, Lee FY, Hwang CC, Hou MC, et al. The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. Scand J Gastroenterol 1995;30:1194–9.
   PubMed Web of Science ®Google Scholar
• Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430–5.
   Google Scholar
• Fernández M, García-Pagán JC, Casadevall M, Mourelle MI, Piqué JM, Bosch J, et al. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 1996;110:1529–39.
   PubMed Web of Science ®Google Scholar
• Wu Y, Burns RC, Sitzmann JV. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology 1993;18:1416–21.
   Google Scholar
• Yokoyama Y, Xu H, Kresge N, Keller S, Sarmadi AH, Baveja R, et al. Role of thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol 2003;284:G453–60.
   Google Scholar
• Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology 1993;18:621–7.
   PubMedGoogle Scholar
• Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994;267:G416–22.
   Google Scholar